Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial

Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y Neven, Leo Heyndrickx, Johan Michiels, Elisabeth Willems, Stéphane De Craeye, Antoine Francotte, Félicie Chaumont, Véronique Olislagers, Alexandra Waegemans, Mathieu Verbrugghe, Marie-Noëlle Schmickler, Steven Van Gucht, Katelijne Dierick, Arnaud Marchant, Isabelle Desombere, Kevin K Ariën, Maria E Goossens
doi: https://doi.org/10.1101/2022.03.25.22272599

Article Information

doi 
https://doi.org/10.1101/2022.03.25.22272599
History 
  • March 31, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Pieter Pannus1,*,,
  2. Stéphanie Depickère1,,
  3. Delphine Kemlin2,
  4. Sarah Houben1,
  5. Kristof Y Neven1,
  6. Leo Heyndrickx3,
  7. Johan Michiels3,
  8. Elisabeth Willems3,
  9. Stéphane De Craeye1,
  10. Antoine Francotte1,
  11. Félicie Chaumont1,
  12. Véronique Olislagers2,
  13. Alexandra Waegemans2,
  14. Mathieu Verbrugghe4,
  15. Marie-Noëlle Schmickler4,
  16. Steven Van Gucht1,
  17. Katelijne Dierick1,
  18. Arnaud Marchant2,&,
  19. Isabelle Desombere1,&,
  20. Kevin K Ariën3,5,& and
  21. Maria E Goossens1,&
  1. 1Scientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium
  2. 2Institute for Medical Immunology and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium
  3. 3Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
  4. 4Mensura EDPB, Occupational Health Service, Antwerp, Belgium
  5. 5Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
  1. ↵*Corresponding author Email: pieter.pannus{at}sciensano.be

  1. ↵ These authors contributed equally to this work.

  2. ↵& These authors also contributed equally to this work.

Back to top
Posted March 31, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial
Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y Neven, Leo Heyndrickx, Johan Michiels, Elisabeth Willems, Stéphane De Craeye, Antoine Francotte, Félicie Chaumont, Véronique Olislagers, Alexandra Waegemans, Mathieu Verbrugghe, Marie-Noëlle Schmickler, Steven Van Gucht, Katelijne Dierick, Arnaud Marchant, Isabelle Desombere, Kevin K Ariën, Maria E Goossens
medRxiv 2022.03.25.22272599; doi: https://doi.org/10.1101/2022.03.25.22272599
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area